Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease - Test2 - elhamkhani - TriplyDB

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

http://www.wikidata.org/entity/Q26775152

about

Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data.Progress toward a Respiratory Syncytial Virus Vaccine Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.Ongoing developments in RSV prophylaxis: a clinician's analysis.Adjuvant formulations for virus-like particle (VLP) based vaccines.Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.Setting a trap for respiratory viruses Meeting Report: Harmonization of RSV therapeutics – from design to performance Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015.Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.New Vaccine Technologies to Combat Outbreak Situations Respiratory Syncytial Virus induces the classical ROS-dependent NETosis through PAD-4 and necroptosis pathways activation

P2860

Q31133974-8E6079D6-FDBC-4BFB-9A36-F28CB0BA0BA1 Q36665660-B7C9733B-47A2-4A17-B3A4-6F46C875CDDC Q37002523-D63A63EC-6369-46FF-9DBF-20920676DEFD Q38631747-B6480D49-60ED-485E-BB69-59998087702C Q39303791-045A694D-0671-484D-A835-27DFD60B6C9A Q40093469-D086B243-1B06-4275-AC5F-C11B44C22ABB Q40349822-3168D050-632D-4405-B98E-75B8F2DA79F9 Q40689679-7565BB30-E5CD-40A6-B3B3-DAE2EAAB7AB8 Q46622417-FCFAD64E-A556-4899-9F6A-23B9B66A9179 Q47547530-C8249F7E-B180-487F-B0D1-8AC4FFD7EB9D Q47553049-6878B8FA-2BAC-4898-B510-5252A943FAEA Q49361412-1E37E829-8721-4D8B-A791-C813690A963F Q54095931-66C56B60-719F-4584-A84A-522261C9BFCE Q57072744-16F5B695-DB8D-4EF6-9595-DDCD63630A8C Q58705977-71117884-ECF1-4170-92FE-E16BB3852C41

P2860

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

http://www.wikidata.org/entity/Q26775152

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@ast

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@en

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@nl

type

label

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@ast

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@en

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@nl

prefLabel

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@ast

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@en

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@nl

P1433

Q26775152-2B82E79C-5162-47B7-9CCB-9E5A43B8C11F

P1476

Q26775152-A2FF60D2-4554-48A8-819C-FAB9FC085EC3

P2093

Q26775152-8DFA97D8-3086-46BD-B46A-F87A5B63AE4A

Q26775152-DB35DA30-9271-493F-939D-39132F50C062

P2860

Q26775152-04130663-42B7-4820-9B8D-F9C257E5F3F6

Q26775152-0449CBA0-E463-42FE-B2C6-3873D327D3EC

Q26775152-0AD32A00-2EF8-48EE-8299-5F4320586A3F

Q26775152-0B3A0848-B9A1-4BF0-A1E9-FB1ED2869366

Q26775152-0B44DD04-4138-4BB1-A611-CE60E9F02070

Q26775152-0D48FA25-F1E0-4DC8-BCB8-84070EF38C27

Q26775152-0D608EB2-B46A-47A3-9C5C-EE405A5D6BE0

Q26775152-124C0A2B-1294-4D5A-9A9E-DB86A2BA7862

Q26775152-1879F988-6C32-4891-896F-D55E33CECAC6

Q26775152-23CBFEA5-6156-4576-9A49-9BA22D678A43

P304

Q26775152-42C2CFAC-19CB-4834-BFA8-69B249F7B80A

P31

Q26775152-03650E83-531E-46D3-AE8F-8D2559AACBF8

P3181

Q26775152-5D1AB87B-73AD-412C-8135-7655C5363337

P356

Q26775152-87E3E740-D23A-421B-AFC2-DF7DE06A7221

P407

Q26775152-CEFD77DE-25BB-4BE1-A819-550B2A746B2E

P433

Q26775152-064614C7-F3D5-4B45-8022-669B0A16E8CA

P478

Q26775152-B26F40A2-D096-4797-82EE-A302D4F3EB3D

P50

Q26775152-97521FF0-E465-4190-9891-108371634ABF

P577

Q26775152-17DA835C-ADAA-49C6-B999-B4B475689475

P698

Q26775152-947B8984-6B77-485D-B6B7-1FE5E95A1DF1

P921

Q26775152-4E532A6E-0B04-43B4-A581-397808AC25AD

P932

Q26775152-088CBF7F-B2D5-4CE9-B2FF-06393E0A98C9

P3181

P356

P1433

Clinical and Vaccine Immunology

P1476

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

@en

P2093

Fernando P Polack

http://www.w3.org/2001/XMLSchema#string

Mauricio T Caballero

http://www.w3.org/2001/XMLSchema#string

P2860

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site

An antibody that prevents the hemagglutinin low pH fusogenic transition

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

P304

189-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

862267

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/CVI.00609-15

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Patricio L Acosta

P577

2015-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26677198

http://www.w3.org/2001/XMLSchema#string

P921

clinical chemistry

P932

4783420

http://www.w3.org/2001/XMLSchema#string